Skip to content

Rybelsus side effects: what the label reports

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

The most common Rybelsus side effects in the label's placebo-controlled trials were nausea (11% on 7 mg and 20% on 14 mg, against 6% on placebo), abdominal pain (10% and 11%), diarrhea (9% and 10%), decreased appetite (6% and 9%), vomiting (6% and 8%) and constipation (6% and 5%). The trials enrolled adults with type 2 diabetes. Tell your prescriber about severe abdominal pain or dehydration.

Source: Rybelsus FDA label

Key takeaways

  • Nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation lead the table for adults with type 2 diabetes on Rybelsus.
  • Rybelsus carries a boxed warning, the strongest kind the FDA requires, about thyroid C-cell tumors.
  • It must not be used with a personal or family history of medullary thyroid carcinoma or with MEN 2.
  • Low blood sugar was more frequent when the tablets were used with insulin or sulfonylureas.
  • Tell your prescriber about severe abdominal pain, dehydration, signs of low blood sugar or any planned surgery.

How often it was reported in the label's trials

Rybelsus: Table 2. Adverse Reactions in Placebo-Controlled Trials Reported in ≥5% of Semaglutide Tablets-Treated Patients with Type 2 Diabetes Mellitus · Adults with type 2 diabetes in 2 placebo-controlled trials of semaglutide tablets (Rybelsus); mean duration of exposure was 41.8 weeks. The table excludes hypoglycemia.
ReactionPlacebon=362Semaglutide tablets 7 mgn=356Semaglutide tablets 14 mgn=356
Nausea6%11%20%
Abdominal Pain4%10%11%
Diarrhea4%9%10%
Decreased appetite1%6%9%
Vomiting3%6%8%
Constipation2%6%5%
Rybelsus: Table 3. Hypoglycemia Adverse Reactions in Placebo-Controlled Trials in Patients with Type 2 Diabetes Mellitus · Monotherapy stratum of Table 3: adults with type 2 diabetes in a 26-week placebo-controlled monotherapy trial. Severe hypoglycemia means an episode requiring the assistance of another person.
ReactionPlacebon=178Semaglutide tablets 7 mgn=175Semaglutide tablets 14 mgn=175
Severe0%1%0%
Plasma glucose <54 mg/dL1%0%0%
Rybelsus: Table 3. Hypoglycemia Adverse Reactions in Placebo-Controlled Trials in Patients with Type 2 Diabetes Mellitus · Moderate renal impairment stratum of Table 3: 26-week trial of semaglutide tablets added to metformin and/or sulfonylurea, basal insulin alone or metformin in combination with basal insulin. The label shows no 7 mg arm for this trial.
ReactionPlacebon=161Semaglutide tablets 14 mgn=163
Severe0%0%
Plasma glucose <54 mg/dL3%6%
Rybelsus: Table 3. Hypoglycemia Adverse Reactions in Placebo-Controlled Trials in Patients with Type 2 Diabetes Mellitus · Add-on to insulin stratum of Table 3: 52-week data from a placebo-controlled trial of semaglutide tablets added to insulin with or without metformin.
ReactionPlacebon=184Semaglutide tablets 7 mgn=181Semaglutide tablets 14 mgn=181
Severe1%0%1%
Plasma glucose <54 mg/dL32%26%30%

Rybelsus: Gastrointestinal reactions overall

In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients who received semaglutide tablets than placebo: semaglutide tablets 14 mg once daily (41%), semaglutide tablets 7 mg once daily (32%) and placebo (21%), including severe reactions (semaglutide tablets 14 mg 2.0%, semaglutide tablets 7 mg 0.6%, placebo 0.3%). The majority of reports of nausea, vomiting and/or diarrhea occurred during dose escalation.

Rybelsus: Less common gastrointestinal reactions

abdominal distension (3%, 2% and 1%), dyspepsia (0.6%, 3%, 0.6%), eructation (2%, 0.6%, 0%,), flatulence (1%, 2%, 0%), gastroesophageal reflux disease (2%, 2%, 0.3%) and gastritis (2%, 2%, 0.8%).

Rybelsus: Hypoglycemia with insulin or sulfonylureas

Hypoglycemia was more frequent when semaglutide tablets were used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin.

Rybelsus: Gallbladder disease

In a 4-year CV outcomes trial (Trial 7), cholelithiasis was reported in 1.1% of patients treated with semaglutide 14 mg tablets and in 0.9% of placebo-treated patients.

Rybelsus: Heart rate increase

In placebo-controlled trials, semaglutide tablets 7 mg and 14 mg tablets resulted in a mean increase in heart rate of 1 to 3 beats per minute. There was no change in heart rate in placebo-treated patients.

Rybelsus: Diabetic retinopathy

In the pool of placebo- and active-controlled trials with semaglutide tablets, patients reported diabetic retinopathy related adverse reactions during the trial (4.2% with semaglutide tablets and 3.8% with comparator).

Rybelsus: Pancreatitis

In the pool of placebo- and active-controlled trials with semaglutide tablets, pancreatitis was reported as a serious adverse event in 6 semaglutide tablets -treated patients (0.1 events per 100 patient years) versus 1 in comparator-treated patients (<0.1 events per 100 patient years).

Rybelsus: Amylase and lipase increases

In placebo-controlled trials, patients exposed to semaglutide tablets 7 mg and 14 mg tablets had a mean increase from baseline in amylase of 10% and 13%, respectively and lipase of 30% and 34%, respectively.

Rybelsus: Discontinuation in the 4-year cardiovascular outcomes trial

Study drug was permanently discontinued due to an adverse event in 15.5% of semaglutide tablets-treated patients and 11.6% of placebo-treated patients.

Rybelsus: Hair loss (alopecia), dysesthesia, dizziness and taste changes, postmarketing reports without a rate

The following adverse reactions have been reported during post-approval use of semaglutide, the active ingredient in RYBELSUS and OZEMPIC tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

FDA label: Rybelsus, Revised: 1/2026 (DailyMed version 14)

Warnings on the Rybelsus label

  • Risk of Thyroid C-Cell Tumors

    Semaglutide caused thyroid C-cell tumors in rodents; whether it does in humans is unknown, and the tablets are contraindicated with a personal or family history of MTC or with MEN 2.

    It is unknown whether RYBELSUS and OZEMPIC tablets cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
  • Acute Pancreatitis

    Acute pancreatitis, including fatal cases, has been seen with GLP-1 receptor agonists including semaglutide tablets; stop the drug if pancreatitis is suspected.

    If pancreatitis is suspected, discontinue RYBELSUS or OZEMPIC tablets and initiate appropriate management.
  • Diabetic Retinopathy Complications

    Diabetic retinopathy related reactions were reported in 4.2% with semaglutide tablets versus 3.8% with comparator in pooled glycemic control trials.

    In a pooled analysis of glycemic control trials, patients reported diabetic retinopathy related adverse reactions during the trial (4.2% with semaglutide tablets and 3.8% with comparator)
  • Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin

    Using the tablets with a sulfonylurea or insulin raises the risk of low blood sugar, which may be reduced by lowering the dose of those medicines.

    The risk of hypoglycemia may be lowered by a reduction in the dosage of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
  • Acute Kidney Injury Due to Volume Depletion

    Acute kidney injury, sometimes needing dialysis, has been reported, mostly in people dehydrated by nausea, vomiting or diarrhea.

    Monitor renal function in patients reporting adverse reactions to RYBELSUS or OZEMPIC tablets that could lead to volume depletion, especially during dosage initiation and escalation of RYBELSUS or OZEMPIC tablets.
  • Severe Gastrointestinal Adverse Reactions

    Severe gastrointestinal reactions were reported in 0.6% (7 mg) and 2% (14 mg) of semaglutide tablet patients versus 0.3% on placebo, and the tablets are not recommended in severe gastroparesis.

    In clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients who received semaglutide tablets (7 mg 0.6%, 14 mg 2%) than placebo (0.3%). Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists.
  • Hypersensitivity Reactions

    Serious allergic reactions such as anaphylaxis and angioedema have been reported; stop the tablets if one occurs.

    Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with semaglutide tablets. If hypersensitivity reactions occur, discontinue use of RYBELSUS or OZEMPIC tablets; treat promptly per standard of care and monitor until signs and symptoms resolve.
  • Acute Gallbladder Disease

    Gallstones were reported in 1% of patients on semaglutide tablets 7 mg in placebo-controlled glycemic trials, and in 1.1% versus 0.9% on placebo in a 4-year cardiovascular trial.

    Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In placebo-controlled trials to improve glycemic control, cholelithiasis was reported in 1% of patients treated with semaglutide tablets (7 mg once daily).
  • Pulmonary Aspiration During General Anesthesia or Deep Sedation

    Because the tablets slow stomach emptying, rare cases of aspiration during anesthesia or deep sedation have been reported with GLP-1 receptor agonists; tell providers before planned procedures.

    Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking RYBELSUS or OZEMPIC tablets.

If a side effect has you worried, tell your prescriber about nausea, vomiting or diarrhea that could leave you dehydrated, about severe abdominal pain, and about signs of low blood sugar if you take insulin or a sulfonylurea. Report signs of a serious allergic reaction too. Dose decisions belong to your prescriber.

Rybelsus is semaglutide in a daily tablet. It shares one label with Ozempic tablets, and that label calls the product “semaglutide tablets” throughout its safety section, so the figures below apply to both. They come from two placebo-controlled trials in adults with type 2 diabetes, with a mean exposure of 41.8 weeks. A placebo group gets an inactive treatment instead of the medicine. The weekly Ozempic injection has its own label and its own numbers on the Ozempic side effects page.

What are the most common side effects of Rybelsus?

Six reactions were reported by at least 5% of patients on semaglutide tablets. The figures are for 7 mg and 14 mg, then placebo.

  • Nausea: 11% and 20%, with 6% on placebo.
  • Abdominal pain: 10% and 11%, with 4% on placebo.
  • Diarrhea: 9% and 10%, with 4% on placebo.
  • Decreased appetite: 6% and 9%, with 1% on placebo.
  • Vomiting: 6% and 8%, with 3% on placebo.
  • Constipation: 6% and 5%, with 2% on placebo.

Nausea is the reaction that changes most with the dose. It nearly doubles between 7 mg and 14 mg. The others move by a point or two. Abdominal pain ranks second in this table.

How common are stomach side effects on Rybelsus?

Counted together, gastrointestinal (stomach and bowel) reactions were reported by 32% of patients on 7 mg and 41% on 14 mg, against 21% on placebo. The label says the majority of reports of nausea, vomiting and diarrhea “occurred during dose escalation,” the weeks when the dose is being raised.

Severe reactions were a small part of that total: 0.6% on 7 mg and 2% on 14 mg, against 0.3% on placebo. The label says the tablets are not recommended in people with severe gastroparesis (a stomach that empties very slowly).

It also lists less frequent stomach reactions: abdominal distension (bloating), dyspepsia (indigestion), belching, flatulence (gas), reflux and gastritis.

Does Rybelsus cause low blood sugar?

On its own, rarely in these trials. In the 26-week trial of the tablets alone, 1% of patients on 7 mg had a severe episode and none on 14 mg or placebo. Blood glucose below 54 mg/dL was recorded in no patient on the tablets and 1% on placebo.

That changes with insulin. In the trial of the tablets added to insulin, glucose below 54 mg/dL was reported in 26% of patients on 7 mg and 30% on 14 mg, against 32% on placebo. So it was frequent in every group, including the one that didn’t take semaglutide. The label says hypoglycemia (low blood sugar) was more frequent when the tablets were used with insulin or with sulfonylureas, a type of diabetes pill, and that lowering the dose of those medicines may reduce the risk. That’s a decision for your prescriber.

What is the boxed warning, and what are the serious side effects?

The label carries a boxed warning for thyroid C-cell tumors. A boxed warning is the strongest kind the FDA requires, set apart in a box on the label. Semaglutide causes these tumors in rodents, and the label says it’s unknown whether Rybelsus and Ozempic tablets cause them, “including medullary thyroid carcinoma (MTC), in humans.” The tablets are contraindicated, meaning they must not be used, in patients with a personal or family history of MTC or with MEN 2 (Multiple Endocrine Neoplasia syndrome type 2).

Other warnings, with the label’s figures:

  • Pancreatitis (inflammation of the pancreas): reported as a serious event in 6 patients on semaglutide tablets and 1 comparator patient across the pooled trials.
  • Diabetic retinopathy (eye damage from diabetes): related reactions in 4.2% of patients on the tablets and 3.8% on comparator.
  • Gallbladder disease: gallstones in 1% of patients on 7 mg in the placebo-controlled trials. In a 4-year cardiovascular outcomes trial, 1.1% on 14 mg and 0.9% on placebo.
  • Acute kidney injury, sometimes requiring dialysis (a machine filters the blood), mostly in people dehydrated by nausea, vomiting or diarrhea.
  • Serious allergic reactions, including anaphylaxis, a sudden and severe whole-body reaction, and angioedema, swelling under the skin.
  • Pulmonary aspiration (stomach contents entering the lungs) during general anesthesia or deep sedation.

The label also records a mean heart rate increase of 1 to 3 beats per minute, and lists alopecia (hair loss), dizziness and taste changes among reactions reported after approval. The safety guide walks through each warning.

How many people stop Rybelsus because of side effects?

In the two placebo-controlled trials, 4% of patients on 7 mg and 8% on 14 mg stopped treatment because of gastrointestinal reactions, against 1% on placebo.

The 4-year cardiovascular outcomes trial gives a longer view. The study drug was permanently stopped because of an adverse event in 15.5% of patients on semaglutide tablets and 11.6% on placebo.

When to call your prescriber

The label names specific things to report:

  • Nausea, vomiting or diarrhea that could leave you dehydrated. The label asks prescribers to monitor kidney function in that case, especially while the dose is being started and raised.
  • Severe abdominal pain. The label says to discontinue the tablets if pancreatitis is suspected.
  • Signs of low blood sugar, if you take insulin or a sulfonylurea.
  • Signs of a serious allergic reaction.
  • Any planned surgery or procedure. The label tells patients to let their healthcare providers know beforehand that they take Rybelsus or Ozempic tablets.

Dose decisions belong to your prescriber. The Rybelsus guide covers how the tablet is taken, and the side effects guide compares each reaction across medicines.

Frequently asked questions

What are the most common side effects of Rybelsus?

Nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation. In two placebo-controlled trials in adults with type 2 diabetes, 11% of patients on 7 mg and 20% on 14 mg reported nausea, against 6% on placebo. Abdominal pain was reported by 10% and 11%, against 4%, and diarrhea by 9% and 10%, against 4%.

How long do Rybelsus side effects last?

The label says most reports of nausea, vomiting and diarrhea came during dose escalation, the weeks when the dose is being raised. That describes the whole trial group, not what you personally should expect. If a reaction doesn't ease, raise it with your prescriber.

Does Rybelsus cause hair loss?

Hair loss isn't in the Rybelsus trial table. The label lists alopecia (hair loss) among reactions reported after approval of semaglutide and gives no rate. It notes that such reports are voluntary and come from a group of uncertain size, so it's not always possible to estimate how often they happen or to establish that the drug caused them.

Is Rybelsus safe?

The label doesn't answer with a yes or a no. It carries a boxed warning, the strongest kind the FDA requires: semaglutide causes thyroid C-cell tumors in rodents, and it's unknown whether Rybelsus causes them in humans. Rybelsus must not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2. Whether it suits you is a decision for your prescriber.

What are the serious side effects of Rybelsus?

The label's warnings cover acute pancreatitis, diabetic retinopathy complications (eye damage from diabetes), low blood sugar with insulin or a sulfonylurea, acute kidney injury after dehydration, severe stomach and bowel reactions, serious allergic reactions, acute gallbladder disease and pulmonary aspiration during anesthesia. Severe stomach and bowel reactions were reported by 0.6% of patients on 7 mg and 2% on 14 mg, against 0.3% on placebo.

Sources (2)

  1. 1.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 4
    “A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)”
  2. 2.